Radius Health, Inc., a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that the U.S. Food and Drug Administration (FDA) will  require additional time to complete its review of the New Drug Application (NDA) for Abaloparatide-SC. In a notice received from the FDA…